The Value of Flow Structures
Dr. Emile Loria was the CEO of a French biotechnology company called BioVector Therapeutics, whose science was drug delivery through inhalants. Emile worked diligently with me, over many sessions, to develop the BioVector IPO road show. However, as often happens, the company was acquired instead of going public. Emile then became the CEO of an already-public U.S. biotechnology company called Epimmune, whose science was based on a naturally occurring substance called epitopes. Epimmune had harnessed epitopes to create vaccines to help the body's immune system fight cancer and infectious diseases.
Emile asked me to review the Epimmune presentation that he was scheduled to deliver at a biotechnology conference the following ...
Get Presenting to Win: The Art of Telling Your Story now with the O’Reilly learning platform.
O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.
